Apogee (APGE) Director William A. Jones Jr Sells Shares

What Happened

• William A. Jones Jr., a director of Apogee Therapeutics (APGE), disposed of a total of 67,312 share-equivalents on Sept 3, 2026 in connection with the company’s merger. That total breaks down to 34,824 shares of common stock and 32,488 shares from option-related dispositions (10,370 + 14,461 + 7,657).
• The merger provided $135.11 per share in cash for common stock. The options were cashed out under the merger agreement for a payment equal to the excess of the $135.11 per-share merger consideration over each option’s exercise price. The common-stock portion alone equates to roughly $4.71 million; option proceeds depend on each option’s strike price.

Key Details

• Transaction date: 2026-09-03. Transaction code: D (disposition to the issuer under the Merger Agreement).
• Per-share merger consideration for common stock: $135.11. Options were settled for the spread between $135.11 and their exercise prices.
• Shares disposed: 34,824 common shares; 10,370 + 14,461 + 7,657 from option dispositions (total 67,312 share-equivalents).
• Shares owned after the transaction: not specified in the filing.
• Notable footnotes: F1–Dispositions made pursuant to the June 18, 2026 Merger Agreement; F2–the reported options were vested as of or became fully vested in connection with the merger; F3–each option was cashed out for the excess of $135.11 over the option’s exercise price.
• Filing timeliness: reported for period 2026-09-03 and filed 2026-09-03 (no late filing indicated).

Context

• This was not an open-market sale but a merger-related cash-out: common shares were paid at the merger consideration and options were settled for the spread over their strikes. Such merger-driven dispositions are typically contractual outcomes of deal terms rather than standalone insider sentiment signals.